Home
Sitemap
Glossary
Contact
Email alert
Print
Search
About us
Pipeline
Technologies
Products
Partnering
Investors
Media centre
Media centre
Press releases
Web casts
Notes to editors
Media contact
2010
2009
2008
2007
2006
2005
2004
Press releases 2007
Date
Headline
13/12/07
Oxford BioMedica Initiates Phase I/II Trial of ProSavin® Gene-Based Treatment for Parkinson's Disease
10/12/07
Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax® Phase III Trial in Renal Cancer
05/12/07
Oxford Biomedica Wins Scrip's Licensing Deal of the Year Award
29/11/07
Oxford BioMedica wins techMARK Award
09/11/07
Oxford BioMedica Announces Appointment of JPMorgan Cazenove as Sole Corporate Broker and Joint Financial Adviser
26/10/07
Oxford BioMedica and Sigma-Aldrich Win Key Ruling in Open Bioystems Patent Infringement Dispute
25/10/07
Oxford BioMedica Responds to Share Price Movement and Reports Business Update
11/09/07
Oxford BioMedica Plc Interim Results for the Six Months Ended 30 June 2007
11/09/07
Oxford BioMedica Reaches First Milestone in TroVax
®
Collaboration with sanofi-aventis
07/08/07
Oxford BioMedica Notice of Interim Results for the six months ended 30 June 2007
02/08/07
Oxford BioMedica: Publication Of TroVax
®
Phase II Clinical Trial Data
25/07/07
Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax
®
Phase III Trial in Renal Cancer as Planned
06/07/07
Oxford BioMedica Secures Rights to Endostatin and Angiostatin Genes for Cancer from Children's Hospital Boston
02/07/07
Oxford BioMedica and Sigma-Aldrich Issue Joint Licence for LentiVector
®
Technology to Major Biotechnology Company
22/06/07
Oxford BioMedica Viragen Update
22/06/07
Oxford BioMedica Wins techMARK Mediscience Award for 'Breakthrough of the Year' for its TroVax
®
Licensing Deal with sanofi-aventis
18/06/07
Oxford BioMedica to Present at Piper Jaffray London Health Care Conference
03/06/07
Oxford BioMedica and sanofi-aventis Report Encouraging New TroVax
®
Phase II Trial Results in Renal Cancer
29/05/07
Oxford BioMedica and Collaborators to Present TroVax
®
Phase II Trial Results in Renal Cancer at American Society of Clinical Oncology Meeting
24/05/07
Oxford BioMedica to present at 2007 FBR Growth Conference
17/05/07
Oxford BioMedica Announces that Phase II Results with Hi-8
®
MEL in Melanoma will be presented at American Association of Immunologists Meeting
08/05/07
Oxford BioMedica's Collaborators in Transgenics Achieve Expression Breakthrough using OVA™ System for Therapeutic Protein Production
03/05/07
Oxford BioMedica Annual General Meeting 2007
01/05/07
Oxford BioMedica and Collaborators to Present Preclinical Data for RetinoStat
®
and StarGen™ at 2007 ARVO Annual Meeting
29/03/07
Notice of Annual General Meeting
28/03/07
Oxford BioMedica and sanofi-aventis Enter Global Licensing Agreement to Develop and Commercialise TroVax
®
for Cancer
12/03/07
Oxford BioMedica to Acquire Oxxon Therapeutics
06/03/07
Oxford BioMedica Plc Preliminary Results For The Year Ended 31 December 2006
27/02/07
Oxford BioMedica: Notice of FY2006 Preliminary Results
01/02/07
Oxford BioMedica Extraordinary General Meeting
24/01/07
Oxford BioMedica Reports Avian Transgenic Milestone: Interferon Alpha Expressed in Eggs
16/01/07
Oxford BioMedica Announces Publication of Avian Transgenic Results in Leading U.S. Scientific Journal
10/01/07
Oxford BioMedica's Phase III Trial of TroVax
®
in Renal Cancer Adopted by UK Clinical Trial Network
